Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q4 FY26 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, May 28, 2026
Slide 1: Themis Medicare Limited – Investor Presentation Cover Letter
TML/BSE/NSE/2026-27/07 28th May, 2026 Corporate Relationship Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Mumbai- 400001 Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Scrip Code – 530199 Symbol: THEMI
Slide 2: Themis Medicare Ltd. Result Update Presentation Q4 & FY26
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q4 & FY26
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “The Company witnessed a gradual recovery in profitability during Q4 FY26. Consolidated revenue for the quarter stood at ₹76.5 crore, registering a growth of 6.7% YoY, supported by improvement across key bu
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 97.6 9.8 90.1 78.0 76.5 3.8 71.7 10.9% -5.8 -10.1 -3.1 4.9% Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 -4.0% -8.1% Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 -10.3% PAT (Rs. Cr.) / Margin (%) EPS (Rs.) 11.2% 11.
Slide 8: Consolidated Quarterly Financial Highlights – Q4 FY26
Consolidated Quarterly Financial Highlights – Q4 FY26 Particulars (Rs. Cr.) Q4 FY26 Q4 FY25 Y-o-Y (%) Q3 FY26 Net Revenue 76.53 71.70 6.7% 90.13 Cost of Material Consumed 14.27 18.98 14.50 • Continued growth in API Purchase of SIT 11.46 16.30 11.63 business, partially offset Changes in Inventory (1.
Slide 9: Consolidated Financial Highlights – FY26
Consolidated Financial Highlights – FY26 Particulars (Rs. Cr.) FY26 FY25 Y-o-Y (%) Net Revenue 342.24 405.51 (15.6%) Cost of Material Consumed 57.30 76.31 Purchase of SIT 63.00 73.67 Changes in Inventory 9.17 (17.98) Employee Expenses 93.52 96.38 (3.0%) Other Expenses 118.85 128.10 Total Expenditure
Slide 10: Consolidated Balance Sheet as on 31st Mar'26
Consolidated Balance Sheet as on 31st Mar’26 As on 31st As on 31st As on 31st As on 31st Equity & Liabilities Assets Mar’26 Mar’25 Mar’26 Mar’25 Shareholders Funds 398.58 402.60 Non Current Assets 292.93 284.17 Share Capital 9.21 9.20 Plant, Property & Equipment 166.40 172.03 Other Equity 389.37 393
Slide 11: Company Overview
Company Overview
Slide 12: Snapshot of Company
Snapshot of Company Strategic focus To enhance profitability and cash flow through improved Strong Balance Sheet clinic effectiveness, targeted doctor outreach, operational Total Debt to Equity at 0.25 efficiencies, and stronger presence in Hospital and API in FY25-26 businesses 3 Rs. 923 Cr State o
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – FY26 Hospital Business API, Co. Mkt & Others 24% is major growth 03 driver Trade 26% Hospital 50% n 02 Hospital Business n API Business ▪ Critical Care Division ▪ API Legacy Business ▪ Intensive Care Division ▪ New Product pipeline Businesswise Revenue
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14 14 14 13 R&D 8 1 11 Analytical Lab 5 8 Development Product in a year with 5–8 20-24 documentation FY21-22 FY22-23 FY23-24 FY24-25 FY25-26 Products in work rolling 3–5 31 14
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? ▪ Growing market - Themis has strong foot in door through Critical Care ▪ Market Highly Fragmented unlike West where 3-4 players control 90% market share ▪ Opportunities to grow segments within HB High Entry Barriers ▪ Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position ❑ Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction ❑ Leadership in Anesthesia and Critical Care Strategy ❑ Focus on Hospital business New Target Markets ❑ APIs to be developed - in- house consumption an
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Pradeep Chandan Mr. Amit Sharma / Mr. Rahul Trivedi Tel: +91 9867726686 / 9833541841 Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Adfactors PR Pvt Ltd Website: www.themismedica